Future of anti-VEGF: biosimilars and biobetters

The advent of Anti- VEGFs like Lucentis (Ranibizumab), Eylea (Aflibercept) and off-label Avastin (Bevacizumab) have radically improved visual outcomes in patients of neovascular Age Related Macular Degeneration (nARMD), Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO). It is a matter of...

Descripción completa

Detalles Bibliográficos
Autores principales: Kapur, Monika, Nirula, Suvansh, Naik, Mayuresh P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8725244/
https://www.ncbi.nlm.nih.gov/pubmed/34983660
http://dx.doi.org/10.1186/s40942-021-00343-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8725244/
https://www.ncbi.nlm.nih.gov/pubmed/34983660
http://dx.doi.org/10.1186/s40942-021-00343-3

Ejemplares similares